Lexicon Pharmaceuticals Stock Cash And Equivalents

LXRX Stock

USD 0.36 0 1.21%

Lexicon Pharmaceuticals fundamentals help investors to digest information that contributes to Lexicon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Lexicon Stock. The fundamental analysis module provides a way to measure Lexicon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lexicon Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lexicon Pharmaceuticals Company Cash And Equivalents Analysis

Lexicon Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current Lexicon Pharmaceuticals Cash And Equivalents

61.97 M

Most of Lexicon Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lexicon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Lexicon Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for Lexicon Pharmaceuticals is extremely important. It helps to project a fair market value of Lexicon Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Lexicon Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lexicon Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lexicon Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Property Plant Equipment	Good Will	Intangible Assets	Treasury Stock	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.37	0.51	-0.57	-0.08	0.47	0.18	0.88	0.78	0.97	0.33	0.53	0.35	0.32	0.46	0.74	0.1	0.1	-0.18	-0.13	0.63	-0.16	0.55	0.52	-0.27
Total Stockholder Equity	0.37		0.13	-0.52	0.19	0.18	-0.34	0.35	0.08	0.39	0.39	-0.1	-0.28	0.13	-0.08	0.28	0.43	0.52	-0.33	-0.18	0.32	0.29	0.29	0.27	0.1
Current Deferred Revenue	0.51	0.13		-0.28	-0.41	0.59	0.09	0.65	0.56	0.61	-0.09	0.35	0.28	-0.26	0.37	0.08	-0.4	-0.13	0.32	0.44	0.7	-0.52	-0.04	0.0	0.14
Net Debt	-0.57	-0.52	-0.28		-0.37	-0.17	0.5	-0.36	-0.15	-0.52	-0.35	-0.15	0.41	-0.43	-0.1	-0.62	-0.09	-0.56	0.63	0.42	-0.61	-0.22	-0.24	-0.09	0.4
Retained Earnings	-0.08	0.19	-0.41	-0.37		-0.21	-0.06	-0.16	-0.18	-0.13	0.4	-0.7	-0.39	0.56	-0.72	0.07	0.41	0.56	-0.85	-0.88	0.05	0.57	0.54	0.38	-0.67
Accounts Payable	0.47	0.18	0.59	-0.17	-0.21		0.04	0.65	0.73	0.47	0.24	0.25	0.51	0.01	0.24	0.43	-0.07	-0.48	0.13	0.1	0.23	-0.1	0.24	0.2	-0.14
Net Receivables	0.18	-0.34	0.09	0.5	-0.06	0.04		0.3	0.36	0.23	0.12	0.04	0.56	-0.03	0.03	-0.21	-0.17	-0.2	0.22	0.02	-0.1	-0.13	0.45	0.55	-0.15
Short Term Investments	0.88	0.35	0.65	-0.36	-0.16	0.65	0.3		0.81	0.9	0.16	0.39	0.42	0.15	0.38	0.53	0.1	-0.01	-0.07	0.05	0.59	-0.15	0.57	0.59	-0.09
Total Liab	0.78	0.08	0.56	-0.15	-0.18	0.73	0.36	0.81		0.78	0.18	0.34	0.78	0.12	0.31	0.55	0.01	-0.42	0.13	0.02	0.48	-0.44	0.5	0.47	-0.25
Total Current Assets	0.97	0.39	0.61	-0.52	-0.13	0.47	0.23	0.9	0.78		0.33	0.47	0.38	0.15	0.44	0.59	0.02	0.13	-0.08	0.0	0.67	-0.24	0.52	0.51	-0.18
Short Term Debt	0.33	0.39	-0.09	-0.35	0.4	0.24	0.12	0.16	0.18	0.33		-0.06	0.01	0.22	-0.09	0.26	0.14	0.31	-0.38	-0.42	-0.11	0.51	0.47	0.39	-0.43
Common Stock	0.53	-0.1	0.35	-0.15	-0.7	0.25	0.04	0.39	0.34	0.47	-0.06		0.3	0.02	0.93	0.48	-0.34	-0.32	0.34	0.39	0.07	-0.29	-0.17	-0.13	0.15
Long Term Debt	0.35	-0.28	0.28	0.41	-0.39	0.51	0.56	0.42	0.78	0.38	0.01	0.3		-0.2	0.3	0.14	-0.2	-0.73	0.54	0.28	-0.02	-0.56	0.21	0.25	-0.06
Property Plant Equipment	0.32	0.13	-0.26	-0.43	0.56	0.01	-0.03	0.15	0.12	0.15	0.22	0.02	-0.2		-0.03	0.59	0.5	0.23	-0.75	-0.77	0.1	0.42	0.59	0.47	-0.51
Good Will	0.46	-0.08	0.37	-0.1	-0.72	0.24	0.03	0.38	0.31	0.44	-0.09	0.93	0.3	-0.03		0.35	-0.31	-0.32	0.37	0.53	0.03	-0.28	-0.12	-0.03	0.37
Intangible Assets	0.74	0.28	0.08	-0.62	0.07	0.43	-0.21	0.53	0.55	0.59	0.26	0.48	0.14	0.59	0.35		0.25	-0.05	-0.41	-0.42	0.34	0.08	0.4	0.27	-0.44
Treasury Stock	0.1	0.43	-0.4	-0.09	0.41	-0.07	-0.17	0.1	0.01	0.02	0.14	-0.34	-0.2	0.5	-0.31	0.25		0.29	-0.49	-0.44	-0.03	0.4	0.51	0.5	0.01
Net Tangible Assets	0.1	0.52	-0.13	-0.56	0.56	-0.48	-0.2	-0.01	-0.42	0.13	0.31	-0.32	-0.73	0.23	-0.32	-0.05	0.29		-0.64	-0.41	0.28	0.51	0.24	0.22	-0.12
Long Term Debt Total	-0.18	-0.33	0.32	0.63	-0.85	0.13	0.22	-0.07	0.13	-0.08	-0.38	0.34	0.54	-0.75	0.37	-0.41	-0.49	-0.64		0.85	-0.18	-0.68	-0.59	-0.44	0.56
Capital Surpluse	-0.13	-0.18	0.44	0.42	-0.88	0.1	0.02	0.05	0.02	0.0	-0.42	0.39	0.28	-0.77	0.53	-0.42	-0.44	-0.41	0.85		-0.06	-0.54	-0.57	-0.38	0.81
Deferred Long Term Liab	0.63	0.32	0.7	-0.61	0.05	0.23	-0.1	0.59	0.48	0.67	-0.11	0.07	-0.02	0.1	0.03	0.34	-0.03	0.28	-0.18	-0.06		-0.43	0.19	0.15	-0.14
Short Long Term Debt	-0.16	0.29	-0.52	-0.22	0.57	-0.1	-0.13	-0.15	-0.44	-0.24	0.51	-0.29	-0.56	0.42	-0.28	0.08	0.4	0.51	-0.68	-0.54	-0.43		0.37	0.31	-0.24
Net Invested Capital	0.55	0.29	-0.04	-0.24	0.54	0.24	0.45	0.57	0.5	0.52	0.47	-0.17	0.21	0.59	-0.12	0.4	0.51	0.24	-0.59	-0.57	0.19	0.37		0.97	-0.44
Net Working Capital	0.52	0.27	0.0	-0.09	0.38	0.2	0.55	0.59	0.47	0.51	0.39	-0.13	0.25	0.47	-0.03	0.27	0.5	0.22	-0.44	-0.38	0.15	0.31	0.97		-0.23
Capital Stock	-0.27	0.1	0.14	0.4	-0.67	-0.14	-0.15	-0.09	-0.25	-0.18	-0.43	0.15	-0.06	-0.51	0.37	-0.44	0.01	-0.12	0.56	0.81	-0.14	-0.24	-0.44	-0.23

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict Lexicon Pharmaceuticals

Lexicon Cash And Cash Equivalents Changes

Cash And Cash Equivalents Changes

(15.15 Million)

Lexicon Pharmaceuticals reported Cash And Cash Equivalents Changes of (15.95 Million) in 2024

In accordance with the recently published financial statements, Lexicon Pharmaceuticals has 61.97 M in Cash And Equivalents. This is 92.45% lower than that of the Biotechnology sector and 86.14% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 97.71% higher than that of the company.

Lexicon Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lexicon Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lexicon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lexicon Pharmaceuticals by comparing valuation metrics of similar companies.

Lexicon Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.

Lexicon Fundamentals

	Return On Equity	-1.68
	Return On Asset	-0.44
	Operating Margin	(0.77) %
	Current Valuation	1.73 M
	Shares Outstanding	361.49 M
	Shares Owned By Insiders	1.19 %
	Shares Owned By Institutions	84.11 %
	Number Of Shares Shorted	44.74 M
	Price To Earning	21.02 X
	Price To Book	0.90 X
	Price To Sales	4.22 X
	Revenue	31.08 M
	Gross Profit	(52.91 M)
	EBITDA	(184.29 M)
	Net Income	(200.4 M)
	Cash And Equivalents	61.97 M
	Cash Per Share	0.34 X
	Total Debt	108.4 M
	Debt To Equity	0.36 %
	Current Ratio	3.85 X
	Book Value Per Share	0.40 X
	Cash Flow From Operations	(178.78 M)
	Short Ratio	11.94 X
	Earnings Per Share	(0.63) X
	Price To Earnings To Growth	(0.14) X
	Target Price	2.6
	Number Of Employees	103
	Beta	1.05
	Market Capitalization	131.29 M
	Total Asset	298.42 M
	Retained Earnings	(1.97 B)
	Working Capital	200.94 M
	Current Asset	171.5 M
	Current Liabilities	31.77 M
	Net Asset	298.42 M

About Lexicon Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lexicon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexicon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexicon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC